| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Neosalvianen targets cancer cells through cytotoxic mechanisms. The compound exhibits cytotoxic activity against HeLa, HepG2, and OVCAR-3 cell lines, indicating activity against cervical, liver, and ovarian cancer cells. As a nitrogen-containing diterpenoid, it may interact with cellular targets involved in cell proliferation and survival, such as microtubules, topoisomerases, or signaling pathways critical for cancer cell growth. However, specific molecular targets have not been extensively characterized.
|
|---|---|
| ln Vitro |
In vitro, Neosalvianen shows cytotoxic activities against multiple cancer cell lines with the following IC₅₀ values: HeLa (cervical carcinoma) at 63.9 µM, HepG2 (hepatocellular carcinoma) at 59.2 µM, and OVCAR-3 (ovarian carcinoma) at 74.6 µM. These results demonstrate that Neosalvianen has moderate cytotoxicity against these cancer cell lines, with the greatest potency against HepG2 cells. The compound is a nitrogen-containing diterpenoid. Further studies are needed to elucidate its mechanism of cytotoxicity and to evaluate its activity against other cancer cell lines.
|
| ln Vivo |
In vivo activity data for Neosalvianen are not available in the published literature. The compound has been primarily characterized through in vitro cytotoxicity studies against cancer cell lines. Given its cytotoxic activity against HeLa, HepG2, and OVCAR-3 cells, potential in vivo studies could include xenograft mouse models of cervical, liver, or ovarian cancer to evaluate its antitumor efficacy. However, such studies have not been reported for this compound.
|
| Enzyme Assay |
In vitro cytotoxicity assays for Neosalvianen typically involve treating cancer cell lines with varying concentrations of the compound for a specified period (typically 48-72 hours), followed by assessment of cell viability using MTT, SRB, or CCK-8 assays. IC₅₀ values are calculated from dose-response curves. The reported IC₅₀ values for Neosalvianen are 63.9 µM against HeLa cells, 59.2 µM against HepG2 cells, and 74.6 µM against OVCAR-3 cells. The compound's structure can be confirmed by NMR and MS. Purity is ≥98%.
|
| Cell Assay |
In vitro cellular assays for Neosalvianen typically involve evaluation of cytotoxicity in cancer cell lines including HeLa, HepG2, and OVCAR-3. Cells are cultured in appropriate media and treated with serial dilutions of the compound for 48-72 hours. Cell viability is assessed using MTT, SRB, or CCK-8 assays, and IC₅₀ values are calculated from dose-response curves. Apoptosis induction can be confirmed through flow cytometry using Annexin V/PI staining or by measuring caspase activity. The compound is soluble in chloroform, DMSO, and acetone.
|
| Animal Protocol |
In vivo animal experiments for Neosalvianen have not been reported in the published literature. Based on its in vitro cytotoxicity against HeLa, HepG2, and OVCAR-3 cell lines, potential in vivo studies would involve subcutaneous or orthotopic xenograft mouse models using these cancer cell lines. Tumor-bearing mice would be treated with Neosalvianen via oral or intraperitoneal administration, and endpoints would include tumor volume measurement, survival analysis, and histopathological examination of tumor tissues. However, such studies have not been published.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Neosalvianen have not been characterized. The compound has a molecular weight of 319.4 g/mol and a molecular formula of C₂₁H₂₁NO₂. As a lipophilic nitrogen-containing diterpenoid, it is expected to have reasonable membrane permeability and oral bioavailability. The compound is soluble in chloroform, DMSO, and acetone. Storage: desiccated at -20°C. Purity ≥98%.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Neosalvianen has not been extensively documented. The compound's cytotoxic activity against cancer cell lines suggests potential for therapeutic application with manageable toxicity. However, comprehensive toxicological evaluations including normal cell cytotoxicity, acute toxicity, and genotoxicity studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that Danshen and Yunnan Danshen contain new tanshinone, and relevant data is available for reference.
Neosalvianen (CAS# 790673-00-6, molecular formula C₂₁H₂₁NO₂, molecular weight 319.4) is a nitrogen-containing diterpenoid with cytotoxic activity against HeLa (IC₅₀ = 63.9 µM), HepG2 (IC₅₀ = 59.2 µM), and OVCAR-3 (IC₅₀ = 74.6 µM) cell lines. No clinical trials or regulatory approvals have been identified. Purity ≥98%. Storage: desiccated at -20°C. |
| Molecular Formula |
C21H21NO2
|
|---|---|
| Molecular Weight |
319.396945714951
|
| Exact Mass |
319.157228913
|
| CAS # |
790673-00-6
|
| PubChem CID |
11472648
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
24
|
| Complexity |
506
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=COC2=C1C3=C(C4=C2C=CC5=C4CCCC5(C)C)OC(=N3)C
|
| InChi Key |
XIEAHUZPQQITDN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H21NO2/c1-11-10-23-19-14-7-8-15-13(6-5-9-21(15,3)4)17(14)20-18(16(11)19)22-12(2)24-20/h7-8,10H,5-6,9H2,1-4H3
|
| Chemical Name |
5,9,17,17-tetramethyl-3,10-dioxa-8-azapentacyclo[10.8.0.02,6.07,11.013,18]icosa-1(12),2(6),4,7(11),8,13(18),19-heptaene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1309 mL | 15.6544 mL | 31.3087 mL | |
| 5 mM | 0.6262 mL | 3.1309 mL | 6.2617 mL | |
| 10 mM | 0.3131 mL | 1.5654 mL | 3.1309 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
